• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Kadmon, Jinghua collaborate in China

Kadmon, Jinghua collaborate in China

November 23, 2015
CenterWatch Staff

Kadmon has announced a new collaboration and license agreement with China's Jinghua Pharmaceutical to discover, develop and commercialize Kadmon's fully human anti-VEGFR2 and anti-PD-L1 monoclonal antibodies exclusively for Greater China. Kadmon also has licensed to Jinghua its technology and know-how to discover fully human monoclonal antibodies to develop further products for commercialization in the Chinese market.

Kadmon has received a $10 million equity investment from Jinghua and has the potential to receive more than $40 million upon the achievement of key milestones as well as 10% royalties on future net sales.

"This agreement highlights the value of Kadmon's scientific work and the depth of our pipeline, including our biologics platform and these important product candidates," said Harlan W. Waksal, M.D., president and CEO at Kadmon. "We look forward to working with Jinghua and are confident in their resources and expertise to bring these monoclonal antibodies to China."

"We are pleased to partner with Kadmon to develop these VEGFR2 and PD-L1 monoclonal antibodies, which represent commercially validated targets for the treatment of cancer," said Yunzhong Zhou, general manager at Jinghua. "We believe that combining Kadmon's platform with Jinghua's capabilities will help us rapidly develop these assets for the Chinese market."

Upcoming Events

  • 24May

    Powering an Effective Oversight Strategy with Clinical and Operational Insights

  • 25May

    2022 WCG Avoca Quality & Innovation Summit: Own the Future

  • 28Jun

    Effective Root Cause Analysis and CAPA Investigations for the Life Sciences

  • 16Oct

    WCG MAGI's Clinical Research Hybrid Conference - 2022 West

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • Protocol-360x240.png

    Avoid Deviations by Making Protocol Review a Team Effort

  • SelectionProcess-360x240.png

    Give Us a Voice: Sites Clamor for a Say on Vendor Selection

  • Convince-360x240.png

    Use Data and Details to Convince Site Leadership to Add Staff

  • AsktheExpertsBadge-360x240.png

    Ask the Experts: Listing Trial Staff and Others on the Statement of Investigator

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell My Personal Information

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2022. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing